Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer

Clinical Therapeutics

Volumn 38, Issue 3, 2016, Pages 449-458

  Crafton, Sarah M ^a   Salani, Ritu ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

cervical cancer; immunotherapy; Key words anti angiogenesis; PARP inhibitors; targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANCER VACCINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CYTOTOXICITY; FEMALE; HUMAN; MEDLINE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVIX CANCER; ADULT; IMMUNOTHERAPY; UTERINE CERVICAL NEOPLASMS;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTEIN KINASE INHIBITORS; UTERINE CERVICAL NEOPLASMS;

EID: 84961180582     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.02.007     Document Type: Review

References (47)

1. L.A. Torre, F. Bray, R.L. Siegel, and et al. Global cancer statstics, 2012 CA Cancer J Clin 65 2015 87 108
2. B.J. Monk, M.W. Sill, D.S. McMeekin, and et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study J Clin Oncol 27 2009 4649 4655
3. A. Stafl, and R.F. Mattingly Angiogenesis of cervical neoplasia Am J Obstet Gynecol 121 1975 845 852
4. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027 Epub December 7, 2004
5. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803
6. W.F. Cheng, C.A. Chen, C.N. Lee, and et al. Vascular endothelial growth factor and prognosis of cervical carcinoma Obstet Gynecol 96 2000 721 726
7. G.L. Bremer, A.T. Tiebosch, H.W. van der Putten, and et al. Tumor angiogenesis: an independent prognostic parameter in cervical cancer Am J Obstet Gynecol 174 1996 126 131
8. Avastin: Proposed mechanism of action. http://www.avastin-hcp.com/about-avastin/proposed-moa. Accessed November 28, 2015.
9. J.D. Wright, D. Viviano, M.A. Powell, and et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer Gynecol Oncol 103 2006 489 493
10. B.J. Monk, M.W. Sill, R.A. Burger, and et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 27 2009 1069 1074
11. I. Zighelboim, J.D. Wright, F. Gao, and et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer Gynecol Oncol 130 2013 64 68
12. T. Schefter, K. Winter, J.S. Kwon, and et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma Int J Radiat Oncol Biol Phys 88 2014 101 105
13. K.S. Tewari, M.W. Sill, H.J. Long 3rd, and et al. Improved survival with bevacizumab in advanced cervical cancer N Engl J Med 370 2014 734 743
14. K.S. Tewari, M.W. Sill, B.J. Monk, and et al. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study Clin Cancer Res 21 2015 5480 5487
15. B.J. Monk, L. Mas Lopez, J.J. Zarba, and et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 2010 3562 3569
16. B.J. Monk, and L.N. Pandite Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer J Clin Oncol 29 2011 4845
17. H.J. Mackay, A. Tinker, E. Winquist, and et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184 Gynecol Oncol 116 2010 163 167
18. R.P. Symonds, C. Gourley, S. Davidson, and et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Oncol 16 2015 1515 1524
19. C.F. Hung, B. Ma, A. Monie, and et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions Expert Opin Biol Ther 8 2008 421 439
20. P.C. Maciag, S. Radulovic, and J. Rothman The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix Vaccine 27 2009 3975 3983
21. P. Basu, A.O. Mehta, M.M. Jain, and et al. ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer J Clin Oncol 32 2014 5s (abstract 5610)
22. Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT01266460). https://clinicaltrials.gov/ct2/show/NCT01266460?term=NCT01266460&rank=1. Accessed December 1, 2015.
23. ADXS11-001 High Dose HPV+ Cervical Cancer (NCT02164461) https://clinicaltrials.gov/ct2/show/NCT02164461?term=NCT02164461&rank=1. Accessed December 1, 2015.
24. A.M. Kaufmann, P.L. Stern, E.M. Rankin, and et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer Clin Cancer Res 8 2002 3676 3685
25. R.N. Eskander, and K.S. Tewari Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer Clin Ther 37 2015 20 38
26. W.J. van Driel, M.E. Ressing, G.G. Kenter, and et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial Eur J Cancer 35 1999 946 952
27. M.E. Ressing, W.J. van Driel, R.M. Brandt, and et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother 23 2000 255 266
28. Study of the Therapeutic Vaccine (ISA101) to Treat Advanced or Recurrent Cervical Cancer (CervISA) (NCT02128126). https://clinicaltrials.gov/ct2/show/NCT02128126?term=NCT02128126&rank=1. Accessed December 1, 2015.
29. A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer (NCT02501278). https://clinicaltrials.gov/ct2/show/NCT02501278?term=NCT02501278&rank=1. Accessed December 1, 2015.
30. A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer (NCT02172911). https://clinicaltrials.gov/ct2/show/NCT02172911?term=NCT02172911&rank=1. Accessed December 1, 2015.
31. M.A. Postow, M.K. Callahan, and J.D. Wolchok Immune Checkpoint Blockade in Cancer Therapy J Clin Oncol 33 2015 1974 1982
32. P. Zheng, and Z. Zhou Human Cancer Immunotherapy with PD-1/PD-L1 Blockade Biomark Cancer 7 Suppl 2 2015 15 18
33. W. Yang, Y. Song, Y.L. Lu, and et al. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia Immunology 139 2013 513 522
34. A.M. Heeren, B.D. Koster, S. Samuels, and et al. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer Cancer Immunol Res 3 2015 48 58
35. Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer (NCT02257528). https://clinicaltrials.gov/ct2/show/NCT02257528?term=NCT02257528&rank=1. Accessed December 8, 2015.
36. Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (NCT01693783). https://clinicaltrials.gov/ct2/show/NCT01693783?term=NCT01693783&rank=1. Accessed December 1, 2015
37. M.A. Morse, and H.K. Lyerly Checkpoint blockade in combination with cancer vaccines Vaccine 33 51 2015 7377 7385
38. S. Stevanovic, L.M. Draper, M.M. Langhan, and et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells J Clin Oncol 33 14 2015 1543 1550
39. J. Villadolid, and A. Amin Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Transl Lung Cancer Res 4 2015 560 575
40. J.D. Wolchok, A. Hoos, S. O'Day, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
41. V.L. Chiou, and M. Burroto Pseudoprogression and Immune-Related Response in Solid Tumors J Clin Oncol 33 2015 3541 3543
42. M. Masutani, T. Nozaki, K. Nakamoto, and et al. The response of PARP knockout mice against DNA damaging agents Mutat Res 462 2000 159 166
43. S. Shall, and G. de Murcia Poly (ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460 2000 1 15
44. J.M. de Murcia, C. Niedergang, C. Trucco, and et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci U S A 94 1997 7303 7307
45. M. Fukushima, K. Kuzuya, K. Ota, and K. Ikai Poly (ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness Cancer Lett 14 1981 227 236
46. C. Kunos, W. Deng, D. Dawson, and et al. A phase I-II evaluation of veliparib (NS#737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the cervix Int J Gynecol Cancer 25 2015 484 492
47. P.H. Thaker, W.E. Brady, H.A. Lankes, and et al. Limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study ASCO 2015